News
19h
Zacks Investment Research on MSNUnveiling Equifax (EFX) Q2 Outlook: Wall Street Estimates for Key MetricsWall Street analysts expect Equifax (EFX) to post quarterly earnings of $1.92 per share in its upcoming report, which indicates a year-over-year increase of 5.5%. Revenues are expected to be $1.51 ...
EFX is set to report Q2 results on July 22, with EPS and revenues expected to rise on solid USIS, international and Workforce ...
2d
Zacks Investment Research on MSNEquifax (EFX) Earnings Expected to Grow: Should You Buy?The market expects Equifax (EFX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Efx Fragments is available now at an introductory price of $99, though if you already own other Arturia products there's probably a steep discount waiting for you.
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the breakthrough Phase 2b SYMMETRY data.
Explore more
Investors in Equifax Inc (Symbol: EFX) saw new options begin trading today, for the April 2025 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is ...
Akero Therapeutics' week 96 Harmony trial data findings and reporting warrant caution. Click here to see why AKRO stock is a Sell.
Investors interested in Financial Transaction Services stocks are likely familiar with Wex (WEX) and Equifax (EFX). But which of these two companies is the best option for those looking for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results